Rep. Thomas Teams Up With Insmed To Promote Follow-on Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Rep. Bill Thomas continues his crusade for follow-ons and against Amgen in his new role as consultant to Richmond, Va.-based Insmed, which has big plans for follow-on biologics.
You may also be interested in...
Bill Thomas' Battle Plan For Cutting Biologics' 12-Year Exclusivity
The former chairman of the House Ways and Means Committee explains how Senate floor debate is key to forcing revisions in the FOB provisions of the health care reform legislation.
Bill Thomas' Battle Plan For Cutting Biologics' 12-Year Exclusivity
The former chairman of the House Ways and Means Committee explains how Senate floor debate is key to forcing revisions in the FOB provisions of the health care reform legislation.
Amgen Pays $200M To Settle Antitrust Claim
No wrongdoing admitted in case filed by Ortho Biotech over anemia drugs.